Thus, several FXR agonists, such as obeticholic acid (NCT01265498, NCT02548351 and NCT03439254), GS-9674 (NCT02854605 and NCT03449446), tropifexor (NCT02855164), and EDP-305 (NCT02918929 and NCT03421431) are in trials for NASH therapeutics. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.